Irinotecan for malignant mesothelioma
Authors:
- 1 June 2005
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 48 (3) , 423-428
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BLung Cancer, 2001
- Malignant pleural mesotheliomaCurrent Treatment Options in Oncology, 2000
- New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 productionCancer Chemotherapy and Pharmacology, 2000
- Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility studyAnti-Cancer Drugs, 2000
- In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agentsAnti-Cancer Drugs, 2000
- Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesotheliomaCancer, 1999
- Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group BChest, 1998
- Chemotherapy in malignant pleural mesothelioma. A review.Journal of Clinical Oncology, 1996
- Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming unitsAnti-Cancer Drugs, 1994
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958